Search clinical trials for: Nilotinib, Imatinib

Total 4224 results

National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Lung Metastases | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Childhood Synovial Sarcoma | Childhood Desmoplastic Small Round Cell Tumor

United States
M.D. Anderson Cancer Center
Novartis

Completed

Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

No longer available

Nilotinib, for Patients With CML-CP or CML-AP

Chronic Myelogenous Leukemia (CML)
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Nilotinib in PH+, BCR-, ABL+ CML Patients (CML0811)

Chronic Myeloid Leukemia

Italy
Novartis Pharmaceuticals

Completed

Tasigna in Glivec-resistant or Intolerant Patients in CML

CML | Nilotinib | Imatinib Resistant | Imatinib Intolerant

Korea, Republic of
Novartis Pharmaceuticals

Approved for marketing

Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Mexico
University Hospital, Bordeaux

Completed

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) (NiloPost-STIM)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

France
Seoul National University Hospital

Completed

Effect of Nilotinib in Cerebellar Ataxia Patients

Ataxia, Cerebellar | Ataxia, Progressive

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway
Asan Medical Center

Completed

Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK

Gastrointestinal Stromal Tumors

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib (MACS1532)

Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Russian Federation
Novartis Pharmaceuticals

Completed

Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor

Turkey
Novartis Pharmaceuticals

Completed

Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (MACS0439)

Chronic Myeloid Leukemia

Brazil
Samsung Medical Center

Unknown

Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib

Leukemia, Chronic Myeloid
University of Cologne
Sanofi; Novartis; Roche Pharma AG

Completed

First-line Therapy of Stage IV Colorectal Cancer

Stage IV Colorectal Cancer

Germany
Fudan University

Unknown

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Tumor

China
Northwestern University
University of Iowa; University of Rochester; Michael J. Fox Foundation for Parkinson...

Completed

Nilotinib in Parkinson's Disease (NILO-PD)

Parkinson Disease

United States
European LeukemiaNet
Ludwig-Maximilians - University of Munich; Heidelberg University

Active, not recruiting

2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients (NAUT)

Chronic Myeloid Leukemia

Germany, Netherlands
Novartis Pharmaceuticals

Completed

Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Gastrointestinal Stromal Tumors

Japan
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Novartis Pharmaceuticals

Completed

A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (ENACT)

Chronic Myeloid Leukemia

Colombia, Venezuela
Novartis Pharmaceuticals

No longer available

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Chronic Myelogenous Leukemia

Canada
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

Medullary Thyroid Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients

Advanced Solid Tumors

China
Emory University
Novartis

Terminated

Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma

Gastric Adenocarcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases

Prostate Cancer | Metastatic Cancer

United States
Jewish General Hospital
Novartis Pharmaceuticals

Terminated

Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients (GL-CLB-001)

Chronic Lymphocytic Leukemia

Canada
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Testicular Seminoma | Recurrent Ovarian Germ Cell Tumor | Stage II Ovarian Germ Cell Tumor | Stage III Ovarian Germ Cell Tumor | Ovarian Dysgerminoma | Recurrent Malignant Testicular Germ Cell Tumor | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor

United States
Elevar Therapeutics

Completed

A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)

Adenoid Cystic Carcinoma

United States, Korea, Republic of
Shanghai Jiao Tong University Affiliated Sixth...

Unknown

A Phase II Study of Apatinib in STS Patients

Soft Tissue Sarcoma
Hunan Cancer Hospital
Fuzhou Pulmonary Hospital of Fujian; Chia Tai Tianqing Pharmaceutical Group...

Recruiting

Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer

Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
New Mexico Cancer Care Alliance
Novartis; Fred Hutchinson Cancer Center

Completed

Study of Gleevec and Weekly Paclitaxel in Patients Aged 70 or Older With Advanced Non-small Cell Lung Cancer (6137p)

Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

Rheumatoid Arthritis

Austria, United Kingdom, Canada, Finland
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

China
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis (SELECTION)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Germany, Australia, Italy, Hong Kong, India, Singapore, Canada, Korea, Republic of, United Kingdom, New Zealand, Ireland, France, Poland, Japan, Switzerland, Croatia, Belgium, Malaysia and more
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Chronic Phase Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (ENESTxtnd)

Chronic Myeloid Leukemia

Canada, Egypt, Saudi Arabia, Australia, Lebanon, South Africa, Israel, Russian Federation, Brazil, Thailand, Malaysia, Argentina, Taiwan, India, Oman, United Arab Emirates, Tunisia, Mexico, Algeria
Georgetown University
National Institutes of Health (NIH)

Recruiting

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States
Novartis Pharmaceuticals

Completed

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Acute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Italy, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Institut Bergonié
Novartis Pharmaceuticals

Withdrawn

Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer (ZAK-0)

Colon Cancer

France
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Completed

A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has Spread (NICAM)

Mucosal Lentiginous Melanoma | Acral Lentiginous Malignant Melanoma

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Gastrointestinal Stromal Tumors

Germany, Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
Fox Chase Cancer Center

Terminated

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST) (07060)

Gastrointestinal Stromal Tumors

United States

Search clinical trials for: Nilotinib, Imatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations